• Lindsley R.C., Mar B.G., Mazzola E., et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. In press, Blood, 2014.
  • Coutinho R., Clear A.J., Mazzola E., et al. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. In press, Haematologica, 2014.
  • Stone R., Mazzola E., Neuberg D. et al.  A phase III open label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia (sAML). In press, J Clin Oncol, 2014.
  • Mazzola, E., Chipman J., Cheng S.-C. and Parmigiani G. Recent BRCAPRO updates significantly improve calibration. Cancer Epidemiology Biomarkers & Prevention, 23, 1689-1695, 2014.
  • Mazzola E., Cheng S.-C. and Parmigiani G. The Penetrance of Ductal Carcinoma in Situ Among BRCA1 and BRCA2 Mutation Carriers. Breast Cancer Res Treat., 137(1), 315-318, 2013. doi:10.1007/s10549-012-2345-5
  • Coopey S.B., Mazzola E., Buckley J.M., et al. Clarifying the Risk of Breast Cancer in Women with Atypical Breast Lesions.
    Breast Cancer Res Treat., 136(3), 627-633, 2012. doi:10.1007/s10549-012-2318-8     
  • Mazzola E., and Muliere P., Reviewing alternative characterizations of Meixner process. Probability Surveys 8: 127-154, 2011.doi:10.1214/11-PS177.